#LiverSky
LightNews LightNews
lancetgastrohep.bsky.social
Our March issue is now live at www.thelancet.com/gastrohep!

Content includes: #alcohol, #IBD, #HBV, #MASLD, #SIMD (#SIBO) + more!

#GastroSky #LiverSky #MedSky
February 12, 2026 at 8:11 AM
liverpath-hphs.bsky.social
📣Upcoming webinar! March 6, 12-1330 ET

🤔Navigating Challenges in Liver Transplant Pathology

Panelist Drs Kakar (steatosis), Demetris (AMR), Torbenson (TCMR), Fiel (plasma cell-rich rejection), and Zen (Int perspective)

Check your e-mail to register and submit questions!👀 #liversky #pathsky
February 9, 2026 at 8:02 PM
lancetgastrohep.bsky.social
New World Report in @thelancet.com examines the controversial trial of hepatitis B virus birth dose vaccination that was planned in Guinea-Bissau

#HepSky #LiverSky #IDSky
thelancet.com The Lancet @thelancet.com · 3d
"...randomly assigning newborns to not receive the vaccine denies a safe and life-saving intervention to infants in Guinea-Bissau."

New World Report by Gilbert Nakweya ⤵️ spkl.io/63325AsFTL
A newborn baby being examined at the Simao Mendez central hospital in Bissau. Copyright: Giacomo Pirozzi/Panos Pictures.
February 9, 2026 at 2:19 PM
lancetgastrohep.bsky.social
New @thelancet.com - Efimosfermin alfa (BOS-580) once per month in people with MASH with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled, phase 2 trial

www.thelancet.com/journals/lan...

#LiverSky #MedSky #EndoSky #GastroSky
Efimosfermin alfa (BOS-580) once per month in people with metabolic dysfunction-associated steatohepatitis with F2 or F3 fibrosis: results from a 24-week, randomised, double-blind, placebo-controlled,...
In this phase 2 trial, treatment with efimosfermin once per month was generally well tolerated in participants with biopsy-confirmed MASH and F2 or F3 fibrosis. These results support the further devel...
www.thelancet.com
February 9, 2026 at 2:16 PM
chrismysko.bsky.social
Delighted to share the evolution of @torchuk.bsky.social and our lessons learnt as a road map 🗺️ 🏥

Such a pleasure to work with talented colleagues across the UK to shape this and prime our project pipeline to improve outcomes in liver disease

doi.org/10.1136/flga...

#liversky #gastrosky #EVADE
February 9, 2026 at 11:03 AM
pippa-matt.bsky.social
A protocol for 'MoLo' #liver #health project for the #Mongolian community in #London is now on line: a template for combining #education, healthcare & #research.
wellcomeopenresearch.org/articles/11-72

#HBV #HIV #LiverSky #IDSky #MedSky 🧪
@crick.ac.uk @uclnews.bsky.social @emilymartyn.bsky.social
Photo of researchers from the Francis Crick Institute leading the liver screening event. Find & Treat vans from the UCL inclusion health team to provide safe and secure space for taking blood tests in the community. Community members engage in discussion and provide informed consent for participation in the project. Photos with consent.
February 6, 2026 at 7:28 PM
pippa-matt.bsky.social
Our preprint addresses therapeutic drug monitoring for #HBV #hepatitisB. It may sound niche, but is a huge clinical & research gap. Better understanding could inform better #treatment & improve outcomes. 🧪💊
#LiverSky #MedSky #IDSky #Pharmacology #TDM #tenofovir
www.researchsquare.com/article/rs-8...
Evidence for a relationship between concentrations of nucleos/tide analogue agents and treatment outcome in chronic hepatitis B infection: A systematic review
Introduction: Treatment of hepatitis B virus (HBV) primarily relies on nucleos(t)ide analogues to achieve viral suppression, with tenofovir or entecavir as first-line agents. Expanding treatment and i...
www.researchsquare.com
February 6, 2026 at 7:13 PM
transplantrockstar.bsky.social
So… this was going on 15 years ago

Ammonia 158
ALT 1220
AST 1068
Bili 21.8
Albumin 1.2
Na 112
INR 2.5

(And coma)

#medsky #liversky
#transplant

DONATE LIFE!!
💙💚💙💚
February 6, 2026 at 3:15 PM
natrevgastrohep.nature.com
FEBRUARY ISSUE | YEAR IN REVIEW: Viral hepatitis in 2025 "Novel insights into chronic HBV infection"

www.nature.com/articles/s41...

#Hepsky #Liversky
Fig. 1: Diagram illustrating the risk of hepatocellular carcinoma attributable to chronic hepatitis B infection and strategies to mitigate it.
February 2, 2026 at 9:47 AM
natrevgastrohep.nature.com
FEBRUARY ISSUE | YEAR IN REVIEW: MASLD in 2025 "Heart–liver co-management in MASLD: from concept to clinical practice"

www.nature.com/articles/s41...

#Liversky
Fig. 1: Key milestones in heart–liver co-management of MASLD.
February 2, 2026 at 9:47 AM
robbrierley.bsky.social
EMA grants conditional marketing authorisation for semaglutide for treatment of non-cirrhotic MASH with liver fibrosis

#LiverSky #MedSky
ema.europa.eu European Medicines Agency @ema.europa.eu · 13d
📢 EMA recommends: 6 new medicines 💊 for approval, including the first #GLP1 #medicine indicated for a serious liver disease and an extension of indication to the first emergency nasal spray for allergies in children.
#PublicHealth #medsky
www.ema.europa.eu/en/news/meet...
January 30, 2026 at 1:56 PM
medthority.bsky.social
What can primary care providers do to support earlier diagnosis of AATD-associated #LiverDisease? Watch James Stoller challenge common misconceptions about the diagnostic process and highlight education gaps that impact real-world practice #MedSky #LiverSky #MedEd

ow.ly/bJXb50Y3P99
January 26, 2026 at 4:05 PM
robbrierley.bsky.social
Guinea-Bissau Suspends Trump-Backed Hep B Vaccine Trial for Ethical Review www.medpagetoday.com/infectiousdi...

#LiverSky #IDSky #HepSky #MedSky
Guinea-Bissau Suspends Trump-Backed Hep B Vaccine Trial for Ethical Review
But HHS spokesman says the study 'is proceeding as planned'
www.medpagetoday.com
January 23, 2026 at 9:58 AM
paoandrenacci.bsky.social
Paris International Liver Meeting
Successful event ✨
⬆️ High academic level with the best quality evidence.
⬆️ Dynamic and with key messages for clinical practice.
👏 Congratulations to all the speakers!
🙌 I am delighted to have had the opportunity to participate.
#LiverSky
January 22, 2026 at 11:37 AM
liverpath-hphs.bsky.social
Reminder about our abstract competition - deadline January 24! ⏰
#liversky #pathsky
liverpath-hphs.bsky.social Hans Popper Hepatopathology Society @liverpath-hphs.bsky.social · Jan 6
📣Are you a trainee with a liver pathology abstract accepted to #USCAP2026 @uscap.org? Enter our HPHS Trainee Award competition! 🥇🥈🥉awards available. Deadline for submission is January 24!
❔ Info: hanspopperhepatopathologysociety.org/award/
📜Submit: docs.google.com/forms/d/e/1F...
#liversky #pathsky
Dr. Hailey Gosnell accepts the 2024 third place award from Dr. Joe Misdraji for her work: Hepatocellular adenomas with high-risk molecular alterations undetected by “high-risk” B-catenin and/or glutamine synthetase staining patterns Dr. Sandeep Kumar accepts the 2024 second place award from Drs. Joe Misdraji and Dhanpat Jain for his work Intrahepatic Cholangiocarcinoma Histologic Subtypes Correlated with Hidden-Genome Classification Dr. Julianne Szczepanski with her 3rd place (tie) award in the 2025 HPHS Abstract Competition, pictured with her poster, Hepatoid intrahepatic cholangiocarcinoma is a hepatiocellular carcinoma mimic: Detailed morphologic review with molecular and clinical correlation Dr. Mengxue Zhang (left), receiving her 1st place award in the 2025 HPHS Abstract Competition from Education Committee Chair Dr. Joseph Misdraji (right) for her work, Investigating genetic predisposition to oxaliplatin-induced sinusoidal obstructive syndrome in colorectal cancer through routinely available NGS data.
January 20, 2026 at 5:26 PM
gastrotoday.bsky.social
A. muciniphila improved metabolic, hepatic, and gut-barrier outcomes in preclinical #MASLD models, including reduced steatosis, improved insulin sensitivity, and lower liver enzymes. These findings could support gut–liver axis–targeted therapies.
#GISky #LiverSky
A. muciniphila Shows Preclinical Benefit in MASLD | Docwire News
Akkermansia muciniphila supplementation improved metabolic, hepatic, and gut-barrier outcomes in preclinical models of metabolic dysfunction-associated steatotic liver disease.
www.docwirenews.com
January 19, 2026 at 10:27 PM
lancetgastrohep.bsky.social
New research - ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial

www.thelancet.com/journals/lan...

#HepSky #IDSky #LiverSky #MedSky
ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial
ALG-000184 was safe and well tolerated, demonstrated predictable pharmacokinetic properties, and reduced HBV DNA and HBV RNA at all doses regardless of HBeAg status. These results support the evaluati...
www.thelancet.com
January 19, 2026 at 4:55 PM
pippa-matt.bsky.social
Our #liver #health project ‘MoLo’ for the #Mongolian Community in #London: #education, assessment for #diabetes, metabolic liver disease #MASLD, #HIV & viral #hepatitis, & linkage to care. Huge team effort with brilliant engagement.
@who.int @crick.ac.uk @ucl.ac.uk
#HBV #HCV #LiverSky #MedSky
🧪🇲🇳
MoLo project team photo by the University College London inclusion health outreach van with the Mongolian Community Organisation hosting the project. Team members set up in advance for point of care testing Kit for point of care testing for HIV, HBV, HCV and syphilis
January 19, 2026 at 8:19 AM
pippa-matt.bsky.social
A #trial that involves withdrawing a lifesaving #vaccine (backed by decades of safety data) in a low income, high prevalence setting?
Over 1000 new #HBV infections predicted as a result.
Flawed endpoints.
No ethics oversight.
Exploitative, corrupt malpractice.
#LiverSky #MedSky #CDC @gavi.org
🧪
January 15, 2026 at 9:49 PM
natrevgastrohep.nature.com
#liversky
January 15, 2026 at 8:33 PM
medthority.bsky.social
Overcome challenges in diagnosing and managing #AATD #LiverDisease with Medthority. Earn up to 2.5 #CME credits now with accessible resources designed to suit you, whether you like to read, watch, or listen #MedSky #Hepatology #MedEd #LiverSky

ow.ly/n8wu50XXjj9
January 15, 2026 at 4:03 PM
pippa-matt.bsky.social
Interesting to see this from #GSK... but lots of questions that still need answering (especially 'please can we see the data?'). Noting functional cure is still attained for a minority with #Bepi, and only when taken on top of standard of care #therapy with NA agents. #MedSky #LiverSky #HBV #NoHep 🧪
boghuma.bsky.social BK. Titanji @boghuma.bsky.social · Jan 12
GSK put out a teaser regarding Phase 3 clinical trial results of its candidate drug bepirovirsen. They came that a significant proportion of participants who received the drug alongside other antiviral achieved functional cure. I look forward to seeing the data.
www.science.org/content/arti...
New hepatitis B drug could help ‘functionally cure’ some patients
Scientists welcome GSK announcement that two trials succeeded—even though data are still lacking
www.science.org
January 12, 2026 at 9:15 PM
britishlivertrust.bsky.social
Could you be at risk of #LiverDisease?

Our online screener only takes a few minutes to check your risk - it could be the most important thing you do today: https://ow.ly/6Yi450XU4rq

#LoveYourLiver

#LiverSky please share
January 11, 2026 at 10:00 AM
pippa-matt.bsky.social
I'm persevering here @bsky.app ...I like the format, but not close to the engagement I had on X/Twitter for #science comms, & lots of the old community ( #MedSky #LiverSky #PublicHealth #GlobalHealth) haven't made the jump. Many institutes & organisations missing. Now more action on @linkedin.com.
January 9, 2026 at 10:09 PM
lancetgastrohep.bsky.social
Our Feb 2026 issue is now live at www.thelancet.com/gastrohep!

Content includes #colorectalcancer, paediatric #ulcerativecolitis, #cholangiocarcinoma, #viralhepatitis, #MASH + more…

#GastroSky #LiverSky #MedSky #OncSky
January 7, 2026 at 7:38 AM